Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 24 Breast Neoplasms 13 Uterine Cervical Neoplasms 11 Carcinoma, Non-Small-Cell Lung 10 Pancreatic Neoplasms 9 Colorectal Neoplasms 9 Melanoma 8 Neoplasm Metastasis 6 Carcinoma, Ovarian Epithelial 6 Lung Neoplasms 5 Fallopian Tube Neoplasms 5 Vaginal Neoplasms 4 Urogenital Neoplasms 4 Stomach Neoplasms 4 Small Cell Lung Carcinoma 4 Penile Neoplasms 4 Oropharyngeal Neoplasms 4 Anus Neoplasms 4 Vulvar Neoplasms 3 Triple Negative Breast Neoplasms 3 Sarcoma 3 Kidney Neoplasms 3 Endometrial Neoplasms 3 Colonic Neoplasms 3 Carcinoma, Renal Cell 3 Thyroid Carcinoma, Anaplastic 2 Testicular Neoplasms 2 Testicular Germ Cell Tumor 2 Squamous Cell Carcinoma of Head and Neck 2 Recurrence 2

Interventions

fludarabine 1 aldesleukin 1 Interleukin-2 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Cancer Metastatic × aldesleukin × Gynecologic × Clear all

NCT04389229 2020-12-16

OVSTAR

Immetacyte Ltd

Phase 1/2 Withdrawn

Ovarian Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡